Analyzing 4D Molecular Therapeutics (FDMT) & Its Competitors

4D Molecular Therapeutics (NASDAQ:FDMT – Get Free Report) is one of 843 publicly-traded companies in the “Biotechnology” industry, but how does it compare to its peers? We will compare 4D Molecular Therapeutics to similar companies based on the strength of its dividends, institutional ownership, risk, profitability, analyst recommendations, valuation and earnings.

Earnings & Valuation

This table compares 4D Molecular Therapeutics and its peers revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
4D Molecular Therapeutics $92.01 million -$140.11 million -4.35
4D Molecular Therapeutics Competitors $756.96 million $11.71 million -18.49

4D Molecular Therapeutics’ peers have higher revenue and earnings than 4D Molecular Therapeutics. 4D Molecular Therapeutics is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Risk & Volatility

4D Molecular Therapeutics has a beta of 2.92, suggesting that its share price is 192% more volatile than the S&P 500. Comparatively, 4D Molecular Therapeutics’ peers have a beta of -1.84, suggesting that their average share price is 284% less volatile than the S&P 500.

Profitability

This table compares 4D Molecular Therapeutics and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
4D Molecular Therapeutics -208.57% -47.06% -40.05%
4D Molecular Therapeutics Competitors -12,224.09% -202.33% -31.23%

Analyst Ratings

This is a breakdown of recent ratings and target prices for 4D Molecular Therapeutics and its peers, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
4D Molecular Therapeutics 1 0 10 0 2.82
4D Molecular Therapeutics Competitors 9923 15317 45687 1603 2.54

4D Molecular Therapeutics currently has a consensus target price of $30.22, indicating a potential upside of 157.52%. As a group, “Biotechnology” companies have a potential upside of 130.26%. Given 4D Molecular Therapeutics’ stronger consensus rating and higher possible upside, equities research analysts plainly believe 4D Molecular Therapeutics is more favorable than its peers.

Institutional & Insider Ownership

99.3% of 4D Molecular Therapeutics shares are owned by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are owned by institutional investors. 7.9% of 4D Molecular Therapeutics shares are owned by company insiders. Comparatively, 13.0% of shares of all “Biotechnology” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

4D Molecular Therapeutics beats its peers on 8 of the 13 factors compared.

About 4D Molecular Therapeutics

(Get Free Report)

4D Molecular Therapeutics, Inc. is a biotechnology company developing genetic medicines for serious diseases. Its research focuses on adeno-associated virus (AAV) gene therapies, which use engineered viral vectors to deliver therapeutic genetic material to cells. The company’s proprietary Therapeutic Vector Evolution platform is designed to create AAV vectors with targeted properties, including the ability to reach specific tissues. Its investigational programs have included treatments for retinal diseases, cystic fibrosis and Fabry disease.

Receive News & Ratings for 4D Molecular Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 4D Molecular Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.